AstraZeneca PLC AZN NYSE

AstraZeneca PLC (AZN) has shown strong revenue growth over the past 3 years, expanding from $44.4B to $58.7B (average +10%/yr). Net income reached $10.3B, reflecting exceptional earnings expansion at +48.3%/yr on average. The net profit margin is 17.5%, which is high. The company has maintained profitability in all 4 of the past 4 years, demonstrating a consistent earnings track record. The gross margin is 81.9% (high), with a +9.8pp trend over the period. With a $317B market cap and MOAT composite score of 94/100, the company has a strong competitive position.

Criteria proven by this page:

• GROWTH (90/100, Pass) — proving strong growth momentum
• PAST (100/100, Pass) — proving consistent earnings. Looking at the full 36-year history, the company was profitable in 36 of 36 years — a perfect long-term track record
• INCOME (70/100, Pass) — proves strong profitability and pricing power
• MOAT (94/100, Pass) — strong gross margins and market scale prove a durable competitive advantage

Overall SharesGrow Score: 64/100 with 4/7 criteria passed.